Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JOINS
- Development stage
- Phase 4
- Lead developer
- SK Chemicals
- Modality
- Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
JOINS (SKI306X) is a botanical drug developed by SK Chemicals, approved in South Korea for the treatment of osteoarthritis and rheumatoid arthritis. It is a standardized extract derived from three medicinal plants: *Clematis mandshurica*, *Trichosanthes kirilowii*, and *Prunella vulgaris*. The drug exhibits a multi-target mechanism of action, providing anti-inflammatory, analgesic, and cartilage-protective (chondroprotective) benefits. It works by inhibiting the expression and activity of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), as well as matrix metalloproteinases (MMPs) that degrade the extracellular matrix of cartilage. JOINS was the first herbal medicine to be approved as a prescription drug by the Korean Ministry of Food and Drug Safety.
- Brand names
- JOINS
- Other names
- Joins tablet
02
Targets
ALOX5 (Arachidonate 5-lipoxygenase)MMP12 (Macrophage Metalloelastase)
Beyond the preview
Go deeper on JOINS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JOINS.